EPZ5676: Potent and Selective DOT1L Inhibitor for MLL Leukemia and Epigenetic Cancer Research

Executive Summary: EPZ5676 is a highly selective DOT1L inhibitor with sub-nanomolar potency (IC50: 0.8 nM, Ki: 80 pM), demonstrating over 37,000-fold selectivity against other methyltransferases, making it a gold-standard for biochemical and cellular studies of H3K79 methylation [APExBIO EPZ5676]. Its inhibition of DOT1L disrupts MLL-fusion target gene expression, leading to strong cytotoxicity in acute leukemia models [Cancer Letters 2025]. In vivo, intravenous dosing (35–70 mg/kg/day, 21 days) in rats yields complete MV4-11 tumor regression with minimal toxicity. Recent studies reveal DOT1L inhibition reprograms innate immunity and enhances response to immunomodulatory drugs in multiple myeloma [Cancer Letters 2025]. EPZ5676 is a solid, water-insoluble compound with high DMSO/ethanol solubility, enabling versatile assay integration.

Biological Rationale

DOT1L (disruptor of telomeric silencing 1-like) is the sole methyltransferase responsible for catalyzing methylation at histone H3 lysine 79 (H3K79), a critical epigenetic mark for transcriptional activation and gene regulation [DOI]. Aberrant DOT1L activity is implicated in MLL-rearranged (mixed-lineage leukemia) and other hematologic malignancies, where H3K79 methylation sustains oncogenic gene expression programs [HDAC1.com]. Multiple myeloma cells exhibit preferential survival dependency on DOT1L, positioning it as a high-priority epigenetic therapeutic target [DOI]. Inhibition of DOT1L downregulates key survival pathways (IRF4-MYC, protein synthesis, and ER stress response), arrests the cell cycle, and induces apoptosis in malignant cells. EPZ5676, commercialized by APExBIO, provides a precise molecular tool to interrogate DOT1L function and therapeutic potential in these contexts.

For a comprehensive background on the evolution of DOT1L inhibitors in leukemia research, see EPZ5676: Potent DOT1L Inhibitor Empowering Leukemia Research, which this article extends by detailing recent immuno-epigenetic findings and in vivo benchmarks.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a competitive inhibitor that occupies the S-adenosyl methionine (SAM) binding pocket of DOT1L, inducing distinct conformational changes that open a hydrophobic pocket beyond the SAM amino acid region [APExBIO]. This high-affinity binding is reflected by an IC50 of 0.8 nM and a Ki of 80 pM in biochemical DOT1L methyltransferase assays. EPZ5676 demonstrates over 37,000-fold selectivity versus other methyltransferases (CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, WHSC1/1L1), confirmed in large panel screens.

In cellular models, EPZ5676 inhibits H3K79 methylation, suppressing MLL-fusion target gene expression, and leads to apoptosis and cell cycle arrest, especially in MLL-rearranged leukemia lines (e.g., MV4-11) [HDAC4.com]. Beyond direct cytotoxicity, DOT1L inhibition in multiple myeloma cells upregulates interferon-regulated genes (IRGs), activates type I IFN and DNA damage signaling, and increases HLA class II gene expression, collectively enhancing immune-mediated anti-tumor activity [DOI].

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L enzymatic activity with an IC50 of 0.8 nM and a Ki of 80 pM in recombinant enzyme assays (APExBIO product page: APExBIO).
• Displays >37,000-fold selectivity for DOT1L over related methyltransferases (CARM1, EZH2, PRMTs, etc.) in in vitro profiling (APExBIO; APExBIO).
• Inhibits H3K79 methylation and downregulates MLL-fusion target gene expression in MV4-11 leukemia cells, with an antiproliferative IC50 of 3.5 nM (4–7 days treatment; APExBIO).
• Induces cell cycle arrest and apoptosis in multiple myeloma and leukemia cell lines (Ishiguro et al., DOI:10.1016/j.canlet.2025.217941).
• Activates type I interferon responses and upregulates HLA class II genes in myeloma cells (Ishiguro et al., DOI).
• Enhances efficacy of immunomodulatory agents (e.g., lenalidomide) via IRG upregulation and IRF4-MYC suppression (Ishiguro et al., DOI).
• In vivo, intravenous administration (35–70 mg/kg/day for 21 days) in nude rats bearing MV4-11 xenografts leads to complete tumor regression with negligible toxicity (APExBIO; APExBIO).

For further translational insights and workflow guidance, consult DOT1L Inhibitor EPZ-5676: Redefining Precision Epigenetic Research, which this article updates by systematically mapping recent immune signaling findings and in vivo data.

Applications, Limits & Misconceptions

Applications:

• Biochemical enzyme inhibition assays for DOT1L specificity and potency.
• Cell proliferation and cytotoxicity assays in MLL-rearranged leukemia and multiple myeloma models.
• Mechanistic studies of H3K79 methylation and transcriptional regulation in cancer.
• Preclinical in vivo efficacy studies (xenograft regression, immune modulation).
• Combination studies with immunomodulatory agents (e.g., lenalidomide).

Common Pitfalls or Misconceptions

• EPZ5676 is not active in water: The compound is insoluble in water; use DMSO or ethanol (with ultrasonic assistance) for stock solutions.
• Non-specific methyltransferase inhibition is minimal: Activity against methyltransferases other than DOT1L is negligible at relevant concentrations.
• Not suitable for chronic in vivo dosing without formulation: Long-term storage of solutions or repeated freeze-thaw cycles can degrade potency.
• Does not rescue acquired immune dysfunction in advanced multiple myeloma: DOT1L inhibition enhances innate immunity, but efficacy may be limited where adaptive immunity is severely compromised [Cancer Letters 2025].
• Not a substitute for genetic knockout: Chemical inhibition does not fully replicate chronic DOT1L deficiency phenotypes.

For a discussion of emerging immuno-epigenetic applications, see DOT1L Inhibitor EPZ-5676: Precision Tool for Immuno-Epigenetics. This article clarifies the boundaries of innate versus adaptive immune modulation by DOT1L inhibition.

Workflow Integration & Parameters

EPZ5676 (product code A4166) is supplied as a solid (molecular weight: 562.71). For biochemical or cell-based assays, dissolve at ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol (ultrasonic assistance may be required). Store powders at –20°C; avoid prolonged storage of solutions. DMSO stocks are stable at –20°C for several months. Recommended working concentrations for cell assays range from 1–100 nM, with typical antiproliferative effects observed at 3.5 nM in MV4-11 cells after 4–7 days. For in vivo work, intravenous delivery at 35–70 mg/kg/day has been validated in xenograft models, yielding complete tumor regression without significant toxicity or weight loss [APExBIO].

For up-to-date protocols and advanced integration in epigenetic workflows, refer to EPZ5676: Potent DOT1L Inhibitor Advancing MLL Leukemia Research. This article expands on those experimental parameters with enhanced selectivity and immune signaling benchmarks.

Conclusion & Outlook

EPZ5676, a potent and selective DOT1L inhibitor commercialized by APExBIO, represents a premier tool for dissecting H3K79 methylation and epigenetic regulation in cancer. Its robust activity profile underpins its adoption in MLL-rearranged leukemia and multiple myeloma research, with demonstrated ability to reprogram innate immune signaling and sensitize tumors to immunomodulatory agents. Ongoing research may extend its utility to additional epigenetic contexts and combinatorial regimens. For detailed product information and ordering, visit the DOT1L inhibitor EPZ-5676 product page.